Atonco announced today that Adrien Reymond, PharmD, B.Eng and EMBA candidate, will lead Regulatory Affairs and Quality.

Adrien, with 15 years of experience in the radiopharmaceutical industry (AAA, a Novartis company), PETNET Solutions (a Siemens company), Atlanpole Biotherapies and consulting for innovative radiopharmaceutical companies, will be in charge of Pharmaceutical and Regulatory Affairs and Quality Assurance to comply with Good Clinical Practices (GCP) and the preparation of the ISO 9001:2015 certification

The entire Atonco team is delighted to welcome Adrien Reymond to the company, both for his expertise and experience in the radiopharmaceutical industry and for his motivation to join the Atonco adventure.


ATONCO is a privately held French company developing molecularly targeted radiopharmaceuticals for oncology applications. Stemming from the world-class nuclear medicine cluster in Nantes, ATONCO and its partners are committed to the clinical use of alpha-emitting radionuclides, in particular astatine-211 (²¹¹At).

For more information, visit

PDF version >>